Provided by Tiger Trade Technology Pte. Ltd.

HARBOR HEALTH CARE ETF

32.46
+0.55781.75%
Post-market: 32.460.00000.00%19:30 EDT
Volume:2K
Turnover:49.64K
Market Cap:41.39M
PE:- -
High:32.46
Open:32.27
Low:32.24
Close:31.90
52wk High:35.61
52wk Low:27.50
Shares:1.28M
Float Shares:1.28M
Volume Ratio:0.40
T/O Rate:0.12%
Dividend:0.08
Dividend Rate:0.23%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

What Does Ascendis Pharma (ASND) Gain From Its CNP Patent Settlement?

Simply Wall St.
·
Oct 07

Adherium Secures Non-Dilutive AUD$700,000 Loan to Support Working Capital

TIPRANKS
·
Oct 07

Moderna Inc. Stock Slips 7.8%, Underperforms Peers

Dow Jones
·
Oct 07

Lilly’s New Basal Insulin Candidate Clears Key Early Trial Milestone

TIPRANKS
·
Oct 07

General Medicine Raises $120 Mln to Build the Healthcare Store

Reuters
·
Oct 06

General Medicine - Series B Financing Led by Andreessen Horowitz (a16z), with Participation from Matrix, Vxi Capital, Eli Lilly and Company

THOMSON REUTERS
·
Oct 06

Cognizant, Gilead Sign 5-Year Tech Extension Covering DevOps, AI Tools

MT Newswires Live
·
Oct 06

Ascendis Says Pooled PaTH Forward/PaTHway Data Show TransCon PTH Normalizes Bone Measures over 5 Years in Hypoparathyroidism

Reuters
·
Oct 06

Cognizant announces five-year extension of its work with Gilead Sciences

TIPRANKS
·
Oct 06

Cognizant - to Support Gilead's Devops and AI Tools Across Selected Technology Programs

THOMSON REUTERS
·
Oct 06

Cognizant Expands AI-Enabled Devops Capabilities for Gilead Sciences

THOMSON REUTERS
·
Oct 06

Entera Bio Appoints Ex-Gilead Executive Laura Hamill to Board of Directors

Reuters
·
Oct 06

Moderna Inc. Stock Rises 6.9%, Outperforms Peers

Dow Jones
·
Oct 06

Eli Lilly Stock (LLY) Gains on Regulatory Win for Experimental Cancer Drug

TIPRANKS
·
Oct 06

Lilly Expands Oncology Footprint with FDA Win for Pancreatic Cancer Drug

Dow Jones
·
Oct 05

Eli Lilly treatment of pancreatic cancer granted orphan designation

TIPRANKS
·
Oct 05

TRex Bio Files for Nasdaq IPO

MT Newswires Live
·
Oct 05

Gate Bioscience Expands Collaboration and License Agreement with Lilly to Target Difficult-to-Drug Proteins

THOMSON REUTERS
·
Oct 05

Eli Lilly Presents New Ebglyss Data from Phase 3 ADorable-1 Pediatric Atopic Dermatitis Study at Fall Clinical 2026

Reuters
·
Oct 05

Nurix, Gilead Extend Research Term for Oncology Program by Two Years for $10 Million Fee

Reuters
·
Oct 05